MedTrace Logo

AIM4 AI and Mechanistic Modeling in Molecular Medicine

NCT06535828 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2025-01-17

No results posted yet for this study

Summary

To assess for potential pitfalls and to assess the feasibility of the approach of analysis of new tumor biopsies for selection of standard of care treatment selection in patients with metastatic hormone receptor positive breast cancer who have developed disease progression on 1st line endocrine therapy combined with a CDK4/6 inhibitor.

Conditions

  • Molecular Medicine

Interventions

DEVICE

AI and mechanic modeling

The data collected from research tests on your blood and tumor samples will be used to develop an AI model for treatment selection.

Sponsors & Collaborators

  • Phase One Foundation

    collaborator OTHER

  • M.D. Anderson Cancer Center

    lead OTHER

Principal Investigators

  • Azadeh Nasrazadani, MD,PHD · M.D. Anderson Cancer Center

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-11-30
Primary Completion
2025-01-15
Completion
2025-01-15

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06535828 on ClinicalTrials.gov